Leaderboards/TP53

TP53

Last updated May 19, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Hervé Avet‐Loiseau
Inserm
339 cit.
2
Lovisa Franzén
Science for Life Laboratory
300 cit.
3
Hartmut Döhner
University Hospital Ulm
252 cit.
4
Julianne Funk
Philipps University of Marburg
219 cit.
5
Scott Kopetz
The University of Texas MD Anderson Cancer Center
213 cit.
6
Jose Espejo Valle-Inclán
European Bioinformatics Institute
183 cit.
7
Enriqueta Felip
Hebron University
164 cit.
8
Collin M. Blakely
University of California, San Francisco
162 cit.
9
Alice Boilève
Inserm
160 cit.
10
Toon Van Gorp
Unknown
160 cit.

Rising Stars Papers

1
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
Journal of Clinical Oncology|2025
112 cit.
2
Mapping spatially resolved transcriptomes in human and mouse pulmonary fibrosis
Nature Genetics|2024
99 cit.
3
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
Blood|2024
125 cit.
4
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations
Nature Genetics|2025
72 cit.
5
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
Nature Medicine|2024
70 cit.
6
Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution
Cell|2025
60 cit.
7
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Annals of Oncology|2024
81 cit.
8
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study
Journal of Clinical Oncology|2024
53 cit.
9
Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer
Gastroenterology|2024
79 cit.
10
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
Annals of Oncology|2024
79 cit.

Rising Stars Reagents

Coming soon

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Wei Gu
Cancer Genetics (United States)
615 cit.
2
Debyani Chakravarty
Memorial Sloan Kettering Cancer Center
379 cit.
3
Li Ding
James S. McDonnell Foundation
191 cit.
4
Karin Jooss
Unknown
183 cit.
5
Ola Landgren
University of Miami
174 cit.
6
Gerald R. Crabtree
Stanford University
159 cit.
7
Jason M. Sheltzer
Yale University
159 cit.
8
Roman K. Thomas
German Cancer Research Center
153 cit.
9
Adam J. Mead
University of Oxford
139 cit.
10
David S. Hong
The University of Texas MD Anderson Cancer Center
123 cit.

Emerging Leaders Papers

1
Understanding the complexity of p53 in a new era of tumor suppression
Cancer Cell|2024
410 cit.
2
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
Cancer Discovery|2023
379 cit.
3
Epigenetic regulation during cancer transitions across 11 tumour types
Nature|2023
191 cit.
4
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
Nature Medicine|2024
122 cit.
5
Genomic Classification and Individualized Prognosis in Multiple Myeloma
Journal of Clinical Oncology|2024
116 cit.
6
Rewiring cancer drivers to activate apoptosis
Nature|2023
159 cit.
7
Oncogene-like addiction to aneuploidy in human cancers
Science|2023
159 cit.
8
Evolutionary trajectories of small cell lung cancer under therapy
Nature|2024
102 cit.
9
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution
Nature Genetics|2023
139 cit.
10
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
Nature Medicine|2024
82 cit.

Emerging Leaders Reagents

Coming soon

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Gideon Rechavi
Sheba Medical Center
15k cit.
2
Robert C. Millikan
University of North Carolina at Chapel Hill
11.5k cit.
3
Roman K. Thomas
University Hospital Cologne
11.4k cit.
4
Arul M. Chinnaiyan
Howard Hughes Medical Institute
10.9k cit.
5
Jessica Zucman‐Rossi
Délégation Paris 5
9.8k cit.
6
Aristotelis Tsirigos
Telio (Norway)
8.5k cit.
7
Nada Jabado
McGill University Health Centre
8k cit.
8
Sean M. Grimmond
The University of Queensland
8k cit.
9
Jennifer R. Grandis
UPMC Hillman Cancer Center
7.6k cit.
10
P. Andrew Futreal
Genomic (Brazil)
7k cit.

All-Time Leaders Papers

1
Comprehensive molecular portraits of human breast tumours
Nature|2012
12.3k cit.
2
Comprehensive molecular characterization of human colon and rectal cancer
Nature|2012
8.6k cit.
3
Integrated genomic analyses of ovarian carcinoma
Nature|2011
8.1k cit.
4
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
Nature|2008
7.8k cit.
5
DNA methylation age of human tissues and cell types
Genome biology|2013
7.2k cit.
6
The Immune Landscape of Cancer
Immunity|2018
6.2k cit.
7
Integrated genomic characterization of endometrial carcinoma
Nature|2013
5.8k cit.
8
Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq
Nature|2012
5k cit.
9
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Nature|2015
4.1k cit.
10
Comprehensive genomic characterization of squamous cell lung cancers
Nature|2012
4k cit.

All-Time Leaders Reagents

Coming soon

Indexing TP53 Reagents

Citation data for reagents in this field is currently compiling.